(-)-Epinephrine (+)-bitartrate: Reference Adrenergic Receptor Agonist for Cardiovascular and Cell Signaling Research

Executive Summary: (-)-Epinephrine (+)-bitartrate (SKU: B1358, APExBIO) is a non-selective adrenergic receptor agonist targeting α₁/α₂ and β₁/β₂/β₃ receptors, with EC₅₀ values of ~5–10 nM for major subtypes, enabling robust activation of adrenergic signaling pathways in vitro and in vivo experiments (APExBIO). It is used to model sympathetic nervous system effects, including vasoconstriction, heart rate acceleration, and bronchodilation. Dosing regimens in research and clinical settings are well-defined, supporting reproducibility and translational value (Shaker et al. 2023). The compound is soluble at ≥16.66 mg/mL in DMSO and ≥22.9 mg/mL in water, but insoluble in ethanol. Storage at -20°C and prompt solution usage are recommended to prevent degradation. Overdose risks and clinical contraindications are established, ensuring controlled application in research and therapy.

Biological Rationale

Epinephrine bitartrate is fundamental for research on adrenergic receptor pharmacology, cardiovascular physiology, and sympathetic nervous system function. As the principal endogenous ligand for adrenergic receptors, (-)-Epinephrine (+)-bitartrate enables experimental modeling of acute stress, vasoconstriction, and bronchodilation mechanisms. In vitro, it serves as a positive control in cell signaling, viability, and proliferation assays (Optimizing Cell Assays with (-)-Epinephrine (+)-bitartrate). In vivo, it models emergency interventions for anaphylactic shock and acute bronchial asthma. Use of high-purity, well-characterized agonists such as (-)-Epinephrine (+)-bitartrate improves reproducibility and comparability across studies (Non-Selective Adrenergic Receptor Agonist), extending insights beyond the scope of previous reviews by focusing on translational applicability.

Mechanism of Action of (-)-Epinephrine (+)-bitartrate

(-)-Epinephrine (+)-bitartrate acts as a non-selective agonist at adrenergic receptors. It stimulates α₁ (EC₅₀ ≈ 5 nM), β₁ (EC₅₀ ≈ 10 nM), and β₂ (EC₅₀ ≈ 8 nM) receptors, triggering downstream G protein signaling cascades. α₁ activation results in vasoconstriction and increased peripheral resistance. β₁ stimulation increases heart rate and myocardial contractility. β₂ activation mediates bronchodilation and inhibits mediator release from mast cells. These effects are dose-dependent and time-resolved, with rapid onset (<30 seconds IM) and short duration (5–15 minutes) in vivo (Shaker et al. 2023). The bitartrate salt enhances water solubility and stability, facilitating precise dosing in experimental protocols and clinical emergencies (APExBIO).

Evidence & Benchmarks

• EC₅₀ values: α₁ ≈ 5 nM, β₁ ≈ 10 nM, β₂ ≈ 8 nM, determined under physiological pH and temperature (APExBIO, product page).
• In vitro assay concentration range: 1 nM–10 μM, validated for cell function, viability, and cytotoxicity endpoints (Optimizing Cell Assays).
• In vivo dosing in canines: 0.15–0.3 mg IM or 2–20 mg intranasal, with hemodynamic monitoring (APExBIO).
• Clinical anaphylaxis treatment: 0.3–0.5 mg IM for adults, 0.01 mg/kg IM for pediatric patients; efficacy established in >90% of acute anaphylaxis cases (Shaker et al. 2023, DOI).
• Solubility: ≥16.66 mg/mL in DMSO, ≥22.9 mg/mL in water at room temperature; insoluble in ethanol (APExBIO).
• Adverse effects: Palpitations and hypertension at supratherapeutic doses; arrhythmia risk in overdose; contraindicated in pheochromocytoma or hyperthyroidism (Shaker et al. 2023).

This article extends prior mechanistic reviews (see Mechanistic Insight) by providing updated, granular dosing and workflow integration details for both research and clinical use.

Applications, Limits & Misconceptions

Research Applications: (-)-Epinephrine (+)-bitartrate is a gold-standard agonist for adrenergic receptor activation studies in cardiovascular, neurobiology, and cell signaling research. It enables controlled induction of vasoconstriction, heart rate changes, and bronchodilation for pharmacodynamic profiling and pathway mapping. The high purity and defined EC₅₀ values facilitate its use as a reference compound and positive control in cell-based assays (Enhancing Cell Assay Reliability), surpassing alternative agonists in reproducibility.

Translational and Clinical Applications: In clinical settings, (-)-Epinephrine (+)-bitartrate is the first-line treatment for anaphylactic shock (Shaker et al. 2023). It also serves as an adjuvant to local anesthesia, prolonging anesthetic duration and minimizing intraoperative bleeding. For acute bronchial asthma exacerbations, it provides rapid bronchodilation.

Common Pitfalls or Misconceptions

• Misapplication in Chronic Settings: Not suitable for chronic hypertension or asthma maintenance due to tachyphylaxis and adverse effect profile.
• Solubility Assumptions: Ethanol is not an appropriate solvent for (-)-Epinephrine (+)-bitartrate; use water or DMSO as recommended (APExBIO).
• Overdosing Risks: Excessive doses can precipitate life-threatening arrhythmias and hypertensive crises, especially in at-risk populations.
• Contraindications: Use is contraindicated in patients with pheochromocytoma or hyperthyroidism due to risk of severe hypertensive response.
• Device Redundancy Misconception: While multiple epinephrine doses may be required in severe anaphylaxis, overprescribing autoinjectors to all patients is not cost-effective and may reduce adherence (Shaker et al. 2023).

Workflow Integration & Parameters

For in vitro cell assays, (-)-Epinephrine (+)-bitartrate is typically reconstituted in sterile water or DMSO at ≥16.66 mg/mL and diluted to 1 nM–10 μM final assay concentrations. Short-term storage at -20°C preserves activity; solutions should be used within hours to minimize oxidation and degradation. In vivo protocols specify 0.15–0.3 mg IM or 2–20 mg intranasally in canine models. Clinical protocols recommend 0.3–0.5 mg IM for adults, 0.01 mg/kg for pediatric patients, with close monitoring for adverse effects. The B1358 kit from APExBIO includes validated preparation and storage guidance. Integration into cell signaling or cardiovascular models requires batch tracking and solvent compatibility checks to ensure reproducibility, as detailed in authoritative lab workflow articles (Optimizing Cell Assays).

Conclusion & Outlook

(-)-Epinephrine (+)-bitartrate remains a benchmark adrenergic receptor agonist for cardiovascular, neurobiology, and cell signaling research. Its defined receptor activation profile, validated dosing ranges, and robust solubility support reproducible, high-impact studies. Researchers should follow manufacturer guidelines for solvent selection, storage, and dosing to maximize data integrity. The compound's clinical use in managing anaphylactic shock and acute asthma underscores its translational relevance. Future research may focus on refining delivery methods, minimizing adverse effects, and exploring its utility in emerging models of sympathetic nervous system regulation. For product details and ordering, consult the APExBIO (-)-Epinephrine (+)-bitartrate product page.